This startup built privacy tech for Sam Altman's eye-scanning project. Read the pitch deck it used to raise $5.5 million.
The startup developed the tech to keep millions of iris scans private for Sam Altman's World.
This is the pitch deck the Austrian startup used to raise funding from Archetype VC, A16z, and others.
An Austrian startup that has built encryption software to share private data without decrypting it has raised $5.5 million in seed funding from investors including A16z and Archetype VC.
Taceo, founded in 2022, has created software that lets companies verify or compute information without decrypting it. That could help payment providers verify transactions or hospitals collaborate on clinical trials without sharing patient data, the startup said.
"They can run the algorithms on our encrypted data without prying on us, but still delivering the service that we find so useful," Lukas Helminger, the cofounder and CEO, told Business Insider.
The startup has combined two encryption techniques to create a cryptographic tool called coSNARKs. Its code is open source, Helminger said, but runs on a cryptographic network that it plans to charge customers a usage-based fee or, in some cases, a flat rate to access.
In 2022, Taceo built the encryption software for World, Sam Altman's iris-scanning verification startup. The partnership came about after the team met representatives for World, then called WorldCoin, at a blockchain conference at Stanford University.
Taceo's software is encrypting the biometric data of over 14 million people using World, which uses eyeball-scanning orbs to prove people's identity.
"This is like a mix between Silicon Valley and German engineering," Helminger told BI, adding that Taceo gets some revenue from the partnership with World.
Helminger told BI that the startup plans to use the fresh capital to grow its team from 12 to between 18 and 20 people, and double down on R&D to address the computational challenges associated with encrypting information for AI.
Over the next six to 12 months, Taceo will target customers in financial services, Helminger said.
The startup's longer-term bet is to deploy its technology for AI use cases, which Helminger called "one of the toughest nuts to crack because it's so computation-heavy."
Archetype VC led Taceo's $5.5 million seed round. The startup also received funding from A16z CSX, the investment firm's crypto startup accelerator, along with Cyber.Fund, a_capital, and Polymorphic Capital.
Here's the 19-page pitch deck Taceo used.
Taceo
Taceo
Taceo
Taceo
Taceo
Taceo
Taceo
Taceo
Taceo
Taceo
Taceo
Taceo
Taceo
Taceo
Taceo
Taceo
Taceo
Taceo
Taceo
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Merging deep tech and biomedical science expertise, ChronicleBio aims to accelerate breakthroughs for millions living with complex chronic conditions
New venture harnesses multi-omic data and AI to develop the largest platform on complex chronic illnesses to drive breakthroughs in POTS, ME/CFS, Long COVID, and other neuroimmune disorders SAN FRANCISCO, Aug. 5, 2025 /PRNewswire/ -- ChronicleBio, a techbio startup focused on radically accelerating insights on neuroimmune disorders, officially launched Tuesday with a bold mission: to build the world's richest, AI-ready data platform for historically overlooked conditions like POTS, ME/CFS, Long COVID, and other complex chronic conditions. ChronicleBio is uniquely led by a founding team that unites elite tech, healthcare, and life sciences: Fidji Simo (Co-founder), current CEO of Instacart and the incoming CEO of OpenAI's applications division, brings deep expertise in consumer-scale technology, product innovation, and health systems transformation. Rohit Gupta (Co-founder & CEO), a biobanking and precision medicine leader who previously oversaw centers at Stanford and UCSF, is the leading scientific and strategic force behind ChronicleBio. Rishi Reddy (Co-founder & Executive Chairman), of Tarsadia Investments, brings an entrepreneurial and venture-backed perspective and a track record in health and life sciences investing. Together, they are tackling a critical gap in biomedical research. ChronicleBio is creating a scalable, ethically driven data ecosystem, integrating clinical, molecular, biospecimen, and patient-reported insights to drive biomarker discovery, patient stratification, and precision therapeutic development. "Entire communities of patients have been ignored for too long, not because their conditions aren't debilitating and prevalent, but because the systems weren't built to understand them," said Fidji Simo, co-founder of ChronicleBio. "ChronicleBio is developing a future where patients can enlist in research, and where the data we collect from them goes directly towards better diagnostics and therapeutics. By building these critical missing datasets and leveraging the massive advances in AI, we aim to accelerate the path to cures." These complex chronic conditions impact nearly 300 million people worldwide, but remain woefully understudied, leaving patients hopeless and without meaningful treatments. It's a disease space desperate for data, and ChronicleBio is offering the scalable solutions to provide it. "Neuroimmune disorders remain some of the most poorly understood in medicine and not for lack of interest, but because the underlying data simply doesn't exist at the scale or structure required for serious breakthroughs," said Rohit Gupta, co-founder and CEO of ChronicleBio. "We're empowering patients and clinicians to get involved in this effort to grow our research-grade biobank and AI-ready data platform so we can close that gap and provide the tools to finally interrogate these diseases with scientific rigor and precision, bringing an end to complex chronic conditions." ChronicleBio partners directly with patients, clinics, and research collaborators to generate longitudinal, multi-modal datasets, including genomics, immune profiling, and real-world outcomes designed for exploration and clinical trial readiness. Its platform is already being used in multiple high-integrity clinics in the U.S. and India, as well as through research collaborations with thousands of patients contributing data and biosamples. "We're creating an ecosystem with global reach, designed not just to generate data, but to fundamentally shift how we discover, develop, and deliver treatments at scale. The opportunity for impact—scientifically, medically, and societally—is enormous," said Rishi Reddy, co-founder and Executive Chairman of ChronicleBio. "We're building the foundational infrastructure for a massive medical need that has been hiding in plain sight." ChronicleBio's founding vision isn't just ambitious. It's personal. Both Simo and Reddy have been diagnosed with at least one of the very conditions the company is focused on researching. Gupta's family also suffers from neuroimmune disorders. The group's world-class expertise is outshined only by its heartfelt determination to rewrite the scientific narrative for the millions of patients overlooked by traditional research and transform lived experience into actionable discovery. ChronicleBio's approach includes: A global biobank platform collecting and connecting data on neuroimmune illnesses A proprietary, AI-ready data engine designed to integrate multi-omic, clinical, and real-world evidence Strategic partnerships with clinics, research consortia, and biotech sponsors looking to unlock hard-to-crack therapeutic areas A decentralized clinical trial network accelerating drug development through real-world access to patients and clinicians For more information, visit or follow ChronicleBio on LinkedIn, X, Instagram, and Facebook. Media Contact:media@ View original content to download multimedia: SOURCE ChronicleBio Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Shopify Q2 Preview: Tariff Noise and GMV Leverage in Focus
Shopify (NASDAQ:SHOP) reports second-quarter 2025 earnings before the open on August 6. Analysts forecast EPS of $0.29 on approximately $2.54 billion in revenue, about 25% YoY growth. Shares are up roughly 92% over the past 12 months and 9% below its 52-week high hit in February 2025. Investor focus remains on GMV, monetization, and merchant exposure to trade friction. Last quarter, total GMV grew 23% to $75 billion. Analysts will look for continued momentum in platform sales, take?rate stability, and revenue per merchant, particularly within Merchant Solutions, where margins are more exposed to cross-border trade costs. Tariffs have become a merchant-level risk. Shopify executives highlighted at Q1 earnings that just 1% of GMV originates from Chinese imports, but cross-border commerce contributed 15% of total GMV. The elimination of the U.S. de minimis exemption for China means merchants now face duties on low-value imports. Shopify has responded with AI-powered tariff guidance tools and expanded duties?collection functionality at checkout to help merchants mitigate cost exposure and friction. AI and international merchant expansion also matter. Shopify continues to roll out AI tools to drive merchant efficiency and boost international cross-border sales. Investors will assess whether Q2 commentary confirms traction in these segments, especially Europe, Managed Markets, and new logistics partnerships, all critical to sustaining profitability as trade friction rises. At a valuation pricing in robust growth, Shopify needs Q2 commentary that reaffirms GMV momentum, merchant loyalty, and the value of its trade?navigation toolkit. Any sign of softening volume or take?rate pressure could signal vulnerability. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Jim Cramer Notes 'CoreWeave Was Good'
CoreWeave, Inc. (NASDAQ:CRWV) is one of the stocks that Jim Cramer spoke about. Answering a caller's query about the company during the lightning round, Cramer said: 'Look, I think CoreWeave, I gotta tell you, CoreWeave was up 11 today, CoreWeave was 11. I think CoreWeave was good. Remember, NVIDIA's better than CoreWeave. I think CoreWeave might even tell you that.' Photo by Chris Liverani on Unsplash CoreWeave (NASDAQ:CRWV) provides a cloud platform optimized for GenAI workloads, as it provides compute, storage, networking, and managed services. The company's tools support AI model training, inference, rendering, and dataset optimization for enterprise-scale deployments. When a caller inquired about the stock during the July 21 episode, he responded: 'Alright, I think I like CoreWeave and I like Michael Intrator, but I would say the stock is $60 billion, and it's going to have to come down and cool off a little bit. There are too many shorts in it. The shorts are covering right now. Once they're finished covering, I think the stock does drop, and you can take a look at it.' While we acknowledge the potential of CRWV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
